Jazz Pharmaceuticals plc — Director's Dealing 2015

May 13, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2015-05-11

Reporting Person: Smith Karen L. (Global Head of R&D and CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-05-11	Ordinary Shares	A	6830.0	$0.0	Acquired	6830	Direct
2015-05-11	Ordinary Shares	A	275.0	$0.0	Acquired	7105	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-05-11	Incentive Stock Option (right to buy)	$176.51	A	2264.0	Acquired	2025-05-10	Common Stock (2264)	Direct
2015-05-11	Non-Qualified Stock Option (right to buy)	$176.51	A	15516.0	Acquired	2025-05-10	Ordinary Shares (15516)	Direct

Footnotes

F1: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest in four successive equal annual installments on the anniversary of the grant date, May 11, 2015.

F2: These restricted stock units are granted pursuant to the Issuer's 2011 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. These units will vest on the first anniversary of the vesting commencement date, April 13, 2015.

F3: These two options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these two options will vest over four years measured from the vesting commencement date, April 13, 2015, with 1/4th vesting on the first anniversary of the vesting commencement date and the remainder vesting in 36 equal monthly installments thereafter.